Therefore the TNF receptor protein superfamilies of polypeptide and reagent are combined to be disclosed, especially those reagents specifically combine GITR, OX40 or CD40. The polypeptide or agency may include fused polypeptide, and especially polypeptide includes GITRL, OX40L or CD40L and/or bi-specific agent. It also discloses using the method for the polypeptide or for inducing and/or enhancing immune response and methods for the treatment of diseases, such as cancer.
